Genes discussed or mentioned in this blog

Genetics, genomics, epigenetics and epigenomics are important recurrent topics in the writing of this blog.  The discussions have included many examples of longevity-related  genes, “shortivity” genes, cancer and inflammation-related genes, gene silencing and gene mutations.  For reference purposes I list the genes I have discussed or mentioned with pointers to the corresponding blog entries.

Telomerase genes

·        “Genetic mutations in the components of telomerase (the RNA template sequence hTERC, reverse transcriptase hTERT, and Syskerin DKC1) have recently been implicated in a variety of bone marrow failure syndromes, idiopathic pulmonary fibrosis, and more recently, acute myeloid leukemia (AML)(ref).”

·        “The crucial role of telomeres in cell turnover and aging is highlighted by patients with 50% of normal telomerase levels resulting from a mutation in one of the telomerase genes. Short telomeres in such patients are implicated in a variety of disorders including dyskeratosis congenita, aplastic anemia, pulmonary fibrosis, and cancer(ref).”

·        See also the blog entry Hoyeraal-Hreidarsson Syndrome and telomere dysfunction

VHL-1 gene:  See the blog entry Another longevity-related biochemical pathway.

P-53 gene:  See the blog entry P53 gene, normal and mutant, in the news.  Also see the blog entry: Senesco and the Factor 5A1 gene.

P-50/65 and NF-kappaB: See the blog entry Autoimmune diseases and lymphoma – Part II: focus on inflammation

P16 and P19 genes: See the blog entries Linking up the theories of aging and Revisiting the naked mole rat – two factors we can emulate for longevity 

WFS1, CISD2, WRN and LMNA genes: See the blog entry Another rare genetic disease, and shortevity genes   

LMNA gene: See the blog entry Progerin, HGPS and a possible new theory of aging. 

AOX gene:  This is a possibly-protective gene missing in humans.  See the blog entry Gene therapy for fruit flies with Parkinson’s Disease 

FRAP1 gene and mTOR:  See the blog entry Longevity genes, mTOR and lifespan. 

FA gene:  See the blog entry A simple treatment for human genetic diseases. 

CFTR, GSTZ1_02 ,pG42R), AKR1C3_35), TYR_02, SCARB1_03, SLC23A1_05. CD80_04, BCL2L1_03, CASP9, EPHX1_15, and ERCC4_01 genes:  See the blog entry Gene variations and diseases – far from simple. 

PINK1 gene:  See the blog entry Mitochondria and Parkinson’s Disease. 

RAS2 and SCH9 genes: See the blog entry Life extension by a factor of 10.

APOE4 and TOMM40  genes: See the blog entry APOE4 gene variant, memory loss and Alzheimer’s Disease risk  

Fas and FasL genes: See the blog entry: Fascinating dance of death and life – Fas, FasL and diseases.  See also : Autoimmune diseases and lymphoma: Part I: focus on Lupus.

TREX1 gene: See the blog entry: Autoimmune diseases and lymphoma: Part I: focus on Lupus.

TNF superfamily of genes within chromosome 6p21.3 and Bcl-2 gene: See the blog entry: Autoimmune diseases and lymphoma – Part III: focus on lymphomas.

P13k gene: See the blog entry: Big pharma is targeting cancer stem cells.  Also see Nrf2 and cancer chemoprevention by phytochemicals, Rosmarinic acid, and Breakthrough telomere research finding.

FTO gene: See the blog entry: The “skinny” about the “fatso” gene FTO. 

FOXO genes:  See the blog entry: FOXO genes and protecting stem cells — What does resveratrol do?  

KLOTHO gene: See the blog entry: Klotho anti-aging gene in the news. 

NRG1 gene: See the blog entry: The NRG1 Gene – an important new tumor suppressor gene? And press sensationalism about it. 

BRCA1, BRCA2, APC, RB1. WIF1, MLH1, TIMP3, PTEN, APC, CD95, RASSF1A, E cadherin, RECK and GSTP1 genes:  See the blog entry: DNA demethylation – a new way of coming at cancers.

Factor 5A1 gene:  See the blog entry: Senesco and the Factor 5A1 gene. 

RPE65 gene: See the blog entry: A gene therapy home run. 

UCP1, PRDM16 genes: See the blog entry: Getting skinny from brown fat.

This entry was posted on 21. December 2009 at 00:14 and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response or trackback from your own site.